[COVID-19 Vaccine] Differential pricing to incentivise pvt manufacturers to increase production, attract foreign players: Centre to Supreme Court

The Central government also said that judicial intervention in such policy matters, though well-meaning, might lead to unforeseen consequences and it should be left to the government to discharge its executive functions.
Supreme Court and Covid vaccine
Supreme Court and Covid vaccine

The rationale behind the new liberalised pricing policy for the COVID-19 vaccine is to ensure scaling up of vaccine coverage, incentivize vaccine manufacturers to rapidly scale up their production, and to attract new vaccine manufacturers, the Central government has told the Supreme Court.

Want to read the full story?

We’re glad you’re enjoying this story. Subscribe to any of our plans to continue reading the story.

Already have an account? Sign In

Related Stories

No stories found.
Bar and Bench - Indian Legal news